Download PDF
Synfacts 2023; 19(02): 0188
DOI: 10.1055/s-0042-1753236
Innovative Drug Discovery and Development

Ervogastat: A Potent and Selective Inhibitor of DGAT2 for the Treatment of NASH

Authors

    Contributor(s):

  • Antonia F. Stepan (Roche)

  • Nadine Kuhl (MSD)

  • Ferdinand H. Lutter (Janssen Pharmaceutica)

Further Information
   Permissions and Reprints

Key words

metabolic stability - ervogastat - NASH - non-alcoholic steatohepatitis - SAR exploration


Publication History

Article published online:
17 January 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany